128 related articles for article (PubMed ID: 29873855)
1. Aquaporin-1 expression in fluoro-edenite-induced mesothelioma effusions: An approach by cell-block procedure.
Angelico G; Ieni A; Caltabiano R; Zeppa P; Tuccari G
Cytopathology; 2018 Oct; 29(5):455-460. PubMed ID: 29873855
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report.
Angelico G; Caltabiano R; Loreto C; Ieni A; Tuccari G; Ledda C; Rapisarda V
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495596
[TBL] [Abstract][Full Text] [Related]
3. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
Mansour MSI; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
Cancer Cytopathol; 2017 Dec; 125(12):908-917. PubMed ID: 28922567
[TBL] [Abstract][Full Text] [Related]
4. Fibulin-3 immunoexpression in malignant mesothelioma due to fluoro-edenite: a preliminary report.
Caltabiano R; Loreto C; Vitale E; Matera S; Miozzi E; Migliore M; Angelico G; Tumino R; Ledda C; Rapisarda V
Future Oncol; 2018 Mar; 14(6s):53-57. PubMed ID: 29664355
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of Aquaporin 1 as a Prognostic Marker in a Prospective Cohort of Malignant Mesotheliomas.
Driml J; Pulford E; Moffat D; Karapetis C; Kao S; Griggs K; Henderson DW; Klebe S
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27376267
[TBL] [Abstract][Full Text] [Related]
6. Occupational exposure to fluoro-edenite and prevalence of anti-nuclear autoantibodies.
Rapisarda V; Loreto C; Castorina S; Romano G; Garozzo SF; Musumeci A; Migliore M; Avola R; Cinà D; Pomara C; Ledda C
Future Oncol; 2018 Mar; 14(6s):59-62. PubMed ID: 29664352
[TBL] [Abstract][Full Text] [Related]
7. Pleural mesothelioma from fluoro-edenite exposure: PACAP and PAC1 receptor. A preliminary report.
Lombardo C; Maugeri G; D'Amico AG; Broggi G; Caltabiano R; Filetti V; Matera S; D'Agata V; Loreto C
Eur J Histochem; 2024 May; 68(2):. PubMed ID: 38699968
[TBL] [Abstract][Full Text] [Related]
8. FBLN-3 as a biomarker of pleural plaques in workers occupationally exposed to carcinogenic fibers: a pilot study.
Rapisarda V; Ledda C; Migliore M; Salemi R; Musumeci A; Bracci M; Marconi A; Loreto C; Libra M
Future Oncol; 2015; 11(24 Suppl):35-7. PubMed ID: 26638921
[TBL] [Abstract][Full Text] [Related]
9. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
10. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
11. Analysis of fibulin-3 after exposure to asbestos-like fibers.
Rapisarda V; Caltabiano R; Musumeci G; Castrogiovanni P; Ferrante M; Ledda C; Lombardo C; Graziano ACE; Cardile V; Loreto C
Environ Res; 2017 Jul; 156():381-387. PubMed ID: 28395242
[TBL] [Abstract][Full Text] [Related]
12. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
Creaney J; Dick IM; Segal A; Musk AW; Robinson BW
Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718
[TBL] [Abstract][Full Text] [Related]
13. Fibulin-3 as biomarker of malignant mesothelioma.
Ledda C; Caltabiano R; Vella F; Matera S; Marconi A; Loreto C; Rapisarda V
Biomark Med; 2019 Jul; 13(10):875-886. PubMed ID: 31237454
[TBL] [Abstract][Full Text] [Related]
14. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
16. Pleural mesothelioma cases in Biancavilla are related to a new fluoro-edenite fibrous amphibole.
Comba P; Gianfagna A; Paoletti L
Arch Environ Health; 2003 Apr; 58(4):229-32. PubMed ID: 14655903
[TBL] [Abstract][Full Text] [Related]
17. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Capkova L; Koubkova L; Kodet R
Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
[TBL] [Abstract][Full Text] [Related]
18. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.
Muruganandan S; Alfonso H; Franklin P; Shilkin K; Segal A; Olsen N; Reid A; de Klerk N; Musk AB; Brims F
Br J Cancer; 2017 Mar; 116(6):703-708. PubMed ID: 28196068
[TBL] [Abstract][Full Text] [Related]
20. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
